Post by MikeTesteron Jan 24, 2025 2:59am
29 Views
Post# 36418409
Reshaping the Standard of Care in Inflammatory and Immunolog
Reshaping the Standard of Care in Inflammatory and ImmunologLooks like APGE is making some serious moves in the inflammatory disease space. Their APG777 with a 75-day half-life is pretty impressive compared to current AD treatments. Phase 2 trial coming in H2 2025 could be a big catalyst. $754M cash runway into Q1 2028 gives them plenty of runway to develop their pipeline.Watching closely on the combo therapy plans with APG777 and APG990 - targeting multiple inflammatory pathways could be a game changer. No debt and strong cash position makes this an interesting biotech play. Might start a small position and add if Phase 2 data looks promising.BTW, BeyondSPX continues to deliver high quality in-depth analysis on just about every US stock out there, even microcaps, for free. Great resource for digging into emerging biotech stories like this one. https://beyondspx.com/article/reshaping-the-standard-of-care-in-inflammatory-and-immunology-diseases-a-closer-look-at-apogee-therapeutics-apge